18f-pf-06445974
Phase 1
18f-pf-06445974 is one of 19 therapeutic programs targeting Alcohol Use Disorder. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
18
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
14 competitors in Depression
#DrugCompanyPhaseTrials
1Brintellix
TakedaApproved
Vraylar
AbbVieApproved
Ulotaront
IIntra-Cellular Therapies, Inc.
Approved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Ketalar
Boehringer IngelheimPhase 2
Glucophage
EMD SeronoPhase 2
Clemastine Fumarate
NovartisPhase 2
Psilocybin
COMPASS PathwaysPhase 2
Otezla
AmgenPhase 1
18f-pf-06445974
NNational Institute of Mental Health (NIMH)
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 18f-pf-06445974. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]